Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (LQDA) is a biopharmaceutical innovator leveraging its proprietary PRINT® Technology to develop precision therapies for pulmonary hypertension and rare cardiopulmonary conditions. This page aggregates official company announcements, providing stakeholders with timely updates on clinical advancements, regulatory milestones, and strategic initiatives.
Investors and researchers will find curated press releases detailing progress in Liquidia’s pipeline, including YUTREPIA™ inhalation powder development, FDA communications, and technology licensing agreements. Content spans clinical trial results, manufacturing updates, and partnership announcements with global pharmaceutical entities.
Key categories include treatment efficacy studies, regulatory filings, intellectual property developments, and operational expansions. All materials adhere to factual reporting standards, ensuring reliable insights into the company’s scientific and business trajectory.
Bookmark this page for streamlined access to Liquidia’s latest verified updates. Combine regular visits with professional financial counsel to inform your investment strategy.
Liquidia Corporation (NASDAQ: LQDA) faces new litigation from United Therapeutics (UTHR) over alleged patent infringement. The lawsuit, filed on May 9, 2025, in North Carolina's U.S. District Court, concerns UTHR's '782 patent and seeks to prevent Liquidia from commercializing YUTREPIA™, their inhaled treprostinil treatment for PAH and PH-ILD.
The disputed '782 patent is from the same family as UTHR's previously invalidated '793 patent. Notably, the '793 patent was declared invalid by the Patent Trial and Appeal Board (PTAB), a decision upheld through multiple appeals including the Supreme Court. The litigation does not affect FDA's ability to approve YUTREPIA, which has a PDUFA date of May 24, 2025.
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, will participate in the BofA Securities 2025 Health Care Conference. The company's CFO/COO Michael Kaseta and CMO Rajeev Saggar will deliver a business update in a fireside chat on May 13, 2025, at 1:40 PM PT / 4:40 PM ET in Las Vegas. Investors can access the webcast through Liquidia's website, where a recording will remain available for at least 30 days after the event.
The U.S. District Court for the District of Columbia has dismissed United Therapeutics' (UTHR) cross-claim challenging Liquidia's (LQDA) amended New Drug Application for YUTREPIA™. The court ruled that UTHR's claim was unripe and lacked standing. The amended NDA seeks to add the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) to YUTREPIA's label.
The FDA has already granted tentative approval for YUTREPIA and set a PDUFA goal date of May 24, 2025. Final approval can be granted after the blocking regulatory exclusivity expires on May 23, 2025. While UTHR maintains the right to appeal, Liquidia's CEO expressed confidence in the FDA's decision to accept and tentatively approve the amended NDA.
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Investors can access the webcast through Liquidia's website, and a replay will be available for one year.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will deliver a fireside chat presentation on Wednesday, April 9, 2025, at 8:45 a.m. ET.
Investors and interested parties can access the live webcast through the 'Investors' section of Liquidia's website. A recorded version of the presentation will remain available on the company's website for a minimum of 30 days after the event.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will deliver a fireside chat presentation on Tuesday, April 8, 2025, at 8:45 a.m. ET.
Investors and interested parties can access the live webcast through the 'Investors' section of Liquidia's website. A recorded version of the presentation will remain available for a minimum of 30 days after the event on the company's website.
Liquidia (NASDAQ: LQDA) announced the FDA's acceptance of its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder. The treatment targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The FDA classified the resubmission as a complete, Class 1 response to the previous action letter from August 16, 2024, which had granted tentative approval for both indications. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.
Liquidia (NASDAQ: LQDA) has announced three poster presentations at the upcoming American Thoracic Society (ATS) 2025 International Conference in San Francisco, scheduled for May 18-21, 2025.
Two posters will present new data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients, focusing on safety, tolerability, and exploratory changes in 6-minute walk distance, quality of life, and cardiac effort. The third poster features a case study from the INSPIRE study, examining long-term safety and tolerability in a PAH patient transitioning from parenteral treprostinil.
The presentations are scheduled for Tuesday, May 20, 2025, from 11:30 a.m. to 1:15 p.m. PT, with Dr. Rajan Saggar, Dr. Daniel Lachant, and Dr. Rodolfo Estrada as presenting authors. All posters will be available on Liquidia's website after the presentations.
Liquidia (NASDAQ: LQDA) reported its full year 2024 financial results, highlighting key developments and financial performance. The company is awaiting final FDA approval for YUTREPIA™ after regulatory exclusivity expires on May 23, 2025, following its tentative approval for PAH and PH-ILD treatment in August 2024.
Financial highlights include:
- Cash position of $176.5 million as of December 31, 2024
- Revenue decreased to $14.0 million from $17.5 million in 2023
- Net loss widened to $130.4 million ($1.66 per share) from $78.5 million in 2023
The company strengthened its financial position through an amended agreement with HealthCare Royalty Partners, providing access to up to $100 million in additional financing. The ASCENT study evaluating YUTREPIA in PH-ILD patients is nearing completion, while development of L606, a twice-daily liposomal treprostinil formulation, continues to progress.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
